IMPRIMIS PHARMACEUTICALS INC's ticker is IMMY and the CUSIP is 45323A201. A total of 15 filers reported holding IMPRIMIS PHARMACEUTICALS INC in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2016 | $125,000 | -13.2% | 49,858 | +31.5% | 0.00% | – |
| Q3 2016 | $144,000 | +16.1% | 37,907 | +14.9% | 0.00% | – |
| Q2 2016 | $124,000 | +51.2% | 32,979 | +59.5% | 0.00% | – |
| Q1 2016 | $82,000 | -47.1% | 20,679 | -7.6% | 0.00% | – |
| Q4 2015 | $155,000 | +9.9% | 22,370 | +2.1% | 0.00% | – |
| Q3 2015 | $141,000 | -15.1% | 21,908 | +7.0% | 0.00% | – |
| Q2 2015 | $166,000 | +15.3% | 20,474 | +13.6% | 0.00% | – |
| Q1 2015 | $144,000 | 0.0% | 18,018 | -6.3% | 0.00% | – |
| Q4 2014 | $144,000 | +8.3% | 19,234 | +7.7% | 0.00% | – |
| Q3 2014 | $133,000 | 0.0% | 17,866 | -6.7% | 0.00% | – |
| Q2 2014 | $133,000 | +6.4% | 19,158 | +2.9% | 0.00% | – |
| Q1 2014 | $125,000 | +257.1% | 18,614 | +78.5% | 0.00% | – |
| Q4 2013 | $35,000 | -22.2% | 10,428 | +4.4% | 0.00% | – |
| Q3 2013 | $45,000 | -42.3% | 9,988 | +8.6% | 0.00% | – |
| Q2 2013 | $78,000 | – | 9,196 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,267,500 | $4,766,000 | 3.18% |
| INSTITUTIONAL & FAMILY ASSET MANAGEMENT, LLC | 622,744 | $2,342,000 | 0.82% |
| MARATHON ASSET MANAGEMENT LP | 833,333 | $3,133,000 | 0.17% |
| BARD ASSOCIATES INC | 65,500 | $246,000 | 0.13% |
| CORRADO ADVISORS, LLC | 31,107 | $117,000 | 0.08% |
| MARATHON CAPITAL MANAGEMENT | 25,000 | $94,000 | 0.05% |
| Granite Investment Partners, LLC | 155,190 | $584,000 | 0.05% |
| BlackRock Investment Management, LLC | 1,966 | $7,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 548 | $2,000 | 0.00% |
| Creative Planning | 750 | $3,000 | 0.00% |